UniProtKB/SwissProt variant VAR

Variant information

Variant position:

271

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LB/B

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Lysine (K) to Arginine (R) at position 271 (K271R, p.Lys271Arg).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are large size and basic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

Likely benign variant; does not affect ApoC-III glycosylation.

Any additional useful information about the variant.

Sequence information

Variant position:

271

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

571

The length of the canonical sequence.

Location on the sequence:

PIIDVINMDNFQYVGASADL K GGFDWNLVFKWDYMTPEQRR

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PIIDVINMDNFQYVGASADLKGGFDWNLVFKWDYMTPEQRR

Mouse                         PIIDVINMDNFQYVGASADLKGGFDWNLVFKWDYMTPEQRR

Drosophila                    PVIDVISMDNFQYIGASADLRGGFDWNLIFKWEYLSPSERA

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 571	Polypeptide N-acetylgalactosaminyltransferase 2
Chain	52 – 571	Polypeptide N-acetylgalactosaminyltransferase 2 soluble form
Topological domain	25 – 571	Lumenal
Disulfide bond	126 – 354
Mutagenesis	282 – 282	W -> A. Loss of enzyme activity.
Beta strand	270 – 274

Literature citations

Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.
Zilmer M.; Edmondson A.C.; Khetarpal S.A.; Alesi V.; Zaki M.S.; Rostasy K.; Madsen C.G.; Lepri F.R.; Sinibaldi L.; Cusmai R.; Novelli A.; Issa M.Y.; Fenger C.D.; Abou Jamra R.; Reutter H.; Briuglia S.; Agolini E.; Hansen L.; Petaejae-Repo U.E.; Hintze J.; Raymond K.M.; Liedtke K.; Stanley V.; Musaev D.; Gleeson J.G.; Vitali C.; O'Brien W.T.; Gardella E.; Rubboli G.; Rader D.J.; Schjoldager K.T.; Moeller R.S.;
Brain 143:1114-1126(2020)
Cited for: VARIANTS CDG2T 200-ARG--GLN-571 DEL; PRO-210 AND 289-GLN--GLN-571 DEL; CHARACTERIZATION OF VARIANTS CDG2T 200-ARG--GLN-571 DEL; PRO-210 AND 289-GLN--GLN-571 DEL; VARIANTS ARG-271 AND VAL-493; CHARACTERIZATION OF VARIANTS ARG-271 AND VAL-493; FUNCTION;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q10471: Variant p.Lys271Arg